Alnylam Days Sales Outstanding vs Roic Analysis
ALNY Stock | USD 149.13 2.09 1.38% |
Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Days Sales Outstanding and its Roic accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Days Sales Outstanding vs Roic
Days Sales Outstanding vs Roic Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Days Sales Outstanding account and Roic. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Alnylam Pharmaceuticals' Days Sales Outstanding and Roic is 0.19. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Roic in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Days Sales Outstanding and Roic is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Alnylam Pharmaceuticals are associated (or correlated) with its Roic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roic has no effect on the direction of Days Sales Outstanding i.e., Alnylam Pharmaceuticals' Days Sales Outstanding and Roic go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Days Sales Outstanding
Roic
Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 704.1M | 868.6M | 1.5B | 1.6B | Total Revenue | 844.3M | 1.0B | 1.8B | 1.9B |
Alnylam Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.4B | 3.4B | 3.6B | 3.5B | 3.8B | 4.0B | |
Other Current Liab | 206.5M | 393.8M | 494.1M | 585.7M | 713.0M | 748.7M | |
Total Current Liabilities | 956.4M | 1.1B | 1.2B | 767.9M | 967.8M | 1.0B | |
Total Stockholder Equity | 1.4B | 1.0B | 588.2M | (158.2M) | (220.6M) | (209.6M) | |
Property Plant And Equipment Net | 646.4M | 706.5M | 733.6M | 738.6M | 725.8M | 762.1M | |
Net Debt | (243.4M) | 24.6M | 177.6M | 453.9M | 1.9B | 2.0B | |
Retained Earnings | (3.7B) | (4.6B) | (5.4B) | (6.6B) | (7.0B) | (6.7B) | |
Accounts Payable | 49.9M | 52.0M | 73.4M | 98.1M | 55.5M | 28.9M | |
Cash | 547.2M | 496.6M | 820.0M | 866.4M | 812.7M | 853.3M | |
Non Current Assets Total | 661.2M | 1.2B | 774.5M | 854.1M | 847.2M | 889.5M | |
Non Currrent Assets Other | 18.1M | 500M | 40.9M | 115.5M | (3.5B) | (3.4B) | |
Other Assets | 32.9M | 40.7M | 101.1M | 115.5M | 132.8M | 139.4M | |
Cash And Short Term Investments | 1.5B | 1.9B | 2.4B | 2.2B | 2.4B | 2.6B | |
Common Stock Shares Outstanding | 109.3M | 115.0M | 118.5M | 121.7M | 124.9M | 70.4M | |
Short Term Investments | 989.0M | 1.4B | 1.6B | 1.3B | 1.6B | 1.7B | |
Liabilities And Stockholders Equity | 2.4B | 3.4B | 3.6B | 3.5B | 3.8B | 4.0B | |
Non Current Liabilities Total | 603.8M | 1.3B | 1.9B | 2.9B | 3.1B | 3.2B | |
Other Current Assets | 98.4M | 90.7M | 111.9M | 132.9M | 126.4M | 68.9M | |
Total Liab | 956.4M | 2.4B | 3.1B | 3.7B | 4.1B | 4.3B | |
Property Plant And Equipment Gross | 425.2M | 706.5M | 733.6M | 738.6M | 948.9M | 996.3M | |
Total Current Assets | 1.7B | 2.2B | 2.9B | 2.7B | 3.0B | 3.1B | |
Accumulated Other Comprehensive Income | (36.5M) | (43.6M) | (33.3M) | (44.7M) | (23.4M) | (22.2M) | |
Property Plant Equipment | 425.2M | 465.0M | 502.0M | 523.5M | 602.0M | 632.1M | |
Short Long Term Debt Total | 303.8M | 521.2M | 997.6M | 1.3B | 2.7B | 2.8B | |
Other Liab | 327.7M | 352.3M | 1.4B | 406.4M | 467.3M | 490.7M | |
Current Deferred Revenue | 396.2M | 352.3M | 301.8M | 42.1M | 102.8M | 119.3M | |
Other Stockholder Equity | 5.2B | 5.6B | 6.1B | 6.5B | 6.8B | 7.2B | |
Short Term Debt | 303.8M | 329.9M | 321.9M | 42.0M | 96.5M | 67.7M | |
Net Receivables | 43.0M | 102.4M | 198.6M | 238.0M | 327.8M | 344.2M | |
Common Stock Total Equity | 1.1M | 1.2M | 1.2M | 1.2M | 1.4M | 770.9K | |
Common Stock | 1.1M | 1.2M | 1.2M | 1.2M | 1.3M | 801.6K | |
Net Tangible Assets | 1.4B | 1.0B | 588.2M | (158.2M) | (182.0M) | (172.9M) | |
Retained Earnings Total Equity | (3.7B) | (4.6B) | (5.4B) | (6.6B) | (5.9B) | (5.6B) | |
Capital Surpluse | 5.2B | 5.6B | 6.1B | 6.5B | 7.4B | 7.8B | |
Inventory | 56.3M | 92.3M | 122.7M | 129.0M | 89.1M | 93.6M | |
Non Current Liabilities Other | 603.8M | 1.6B | 1.7B | 1.5B | 1.6B | 1.7B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 15.974 | Quarterly Revenue Growth 0.548 | Return On Assets (0.03) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.